arq092

Miransertib (ARQ-092) 是一种具有口服活性的，选择性和变构性Akt 抑制剂。它有效抑制利什曼原虫，还是 AKT1-E17K 突变蛋白抑制剂，可研究PI3K AKT 驱动的肿瘤和 Proteus 综合征。

Miransertib hydrochloride (ARQ-092 hydrochloride) is a powerful, orally bioavailable, selective, and allosteric inhibitor of Akt. It exhibits an inhibitory concentration (IC50) of 2.7 nM, 14 nM, and 8.1 nM against Akt1, Akt2, and Akt3, respectively. In addition to its Akt inhibitory activity, Miransertib hydrochloride also demonstrates significant potency as an inhibitor of the AKT1-E17K mutant protein. This compound shows promise in research related to PI3K AKT-driven tumors and Proteus syndrome. Furthermore, Miransertib hydrochloride displays efficacy against Leishmania [1, 2].